Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, announced the publication of a webcast hosted by BioPub, a biotech investment and discussion website found at www.biopub.co. The webcast can be found at this link.
The webcast was moderated by BioPub’s founder and editor in chief, Dr. KSS, MD, Ph.D. Participants from Know Labs included CEO Phil Bosua and Chairman Ron Erickson.
During the webcast, Phil and Ron answered questions regarding the miniaturization of the hardware for the UBAND™, shared a snapshot of a test result representative of recent weeks of testing, and discussed the Company’s goals for the remainder of 2020.
About Know Labs, Inc.
Know Labs, Inc. is a public company whose shares trade under the stock symbol “KNWN.” The Company’s technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The Company refers to its technology as Bio-RFID™. The Bio-RFID technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent pending technology makes it possible to effectively conduct analyses that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The Company’s first product will be the non-invasive UBAND Continuous Glucose Monitor (CGM). Those wishing to stay up to date on the developments at Know Labs can subscribe to the Company’s YouTube channel at this link. For more information, visit the company’s website at www.knowlabs.co.
BioPub is an online subscription service reviewing small-cap biotech companies. It is led by an NIH-trained MD, PhD former medical professor and researcher, and his colleagues. The BioPub team works to identify exceptional companies, representing what it regards as the top decile of biotech investing opportunities on the basis of three concurrent attributes: genuine top-shelf science; credible, competent, and accessible management; and the likelihood that a company’s efforts will permanently alter the landscape of clinical medicine. For more information, visit the company’s website at www.biopub.co.
Safe Harbor Statement
This release and video contain statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2018, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at www.knowlabs.co. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.